Ruxolitinib for the Treatment of Essential Thrombocythemia
Abstract. Deregulated Janus Kinase 2 (JAK2) activation is central to the pathogenesis of most myeloproliferative neoplasms (MPNs), of which essential thrombocythemia (ET) is the most common entity. Patients with ET are risk-stratified according to their risk of thrombo-hemorrhagic complications. Hig...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2018-08-01
|
| Col·lecció: | HemaSphere |
| Accés en línia: | http://journals.lww.com/10.1097/HS9.0000000000000056 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|